Searchable abstracts of presentations at key conferences in endocrinology
Endocrine Abstracts (2019) 63 GP224 | DOI: 10.1530/endoabs.63.GP224


Vall d’Hebron Research Institute (VHIR), Barcelona, Spain.

Epidemiological studies have shown that caffeine increases plasma SHBG levels and also reduce the risk of type 2 diabetes. There are no reports describing any molecular mechanism by which caffeine regulates hepatic SHBG production. The aim of the present study was to explore whether caffeine regulates SHBG production and to determine the associated molecular mechanisms. For this purpose, in vitro and in vivo studies were performed using human HepG2 cells and human SHBG transgenic mice. Our results showed that caffeine treatment did not change SHBG production in HepG2 cells. By contrast, caffeine treatment increased significantly both plasma and hepatic mRNA SHBG levels in human SHBG transgenic mice when compared with control mice. Caffeine treatment increased adiponectin mRNA levels in epididymal adipose tissue of human SHBG transgenic mice and in differentiated 3T3-L1 mouse adipocytes. This caffeine-induced increase in adiponectin in turn upregulated the hepatic levels of HNF-4a in human SHBG transgenic mice. Our results showed for the first time that caffeine upregulates hepatic SHBG expression by increasing adiponectin production in the adipose tissue. These results suggest that the beneficial effects of caffeine in preventing type 2 diabetes development could be mediated by increasing SHBG plasma levels.

Volume 63

21st European Congress of Endocrinology

Lyon, France
18 May 2019 - 21 May 2019

European Society of Endocrinology 

Browse other volumes

Article tools

My recent searches

No recent searches.